TLX Telix Pharmaceuticals Limited
Healthcare$9.57+1.06%ClosedMarket Cap: $3.24B
As of 2026-05-26
Valuation
P/E (TTM)
83.26
PEG
0.60
P/B
6.97
P/S
3.55
EV/EBITDA
132.54
DCF Value
$-182.76
FCF Yield
-1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.8%
Operating Margin
2.1%
Net Margin
-0.9%
ROE
-2.1%
ROA
-0.6%
ROIC
1.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $620.4M | 52.8% | $9.8M | $-7.3M | $— | — |
| FY null | $1.21B | 53.1% | $26.6M | $-10.7M | $— | — |
| Q2 null | $593.1M | 48.6% | $15.8M | $-3.5M | $— | — |
| Q4 null | $594.2M | 64.9% | $68.4M | $38.2M | $— | — |
| FY null | $783.2M | 65.1% | $82.1M | $49.9M | $— | — |
| Q2 null | $189.0M | 65.6% | $13.8M | $11.7M | $— | — |
| Q4 null | $281.7M | 79.5% | $20.1M | $19.5M | $— | — |
| FY null | $502.5M | 62.6% | $51.9M | $5.2M | $— | — |
| Q2 null | $220.8M | 41.1% | $31.4M | $-14.3M | $— | — |
| Q4 null | $136.0M | 33.0% | $-9.7M | $-33.2M | $— | — |
| FY null | $160.1M | 18.3% | $-91.9M | $-104.1M | $— | — |
| Q2 null | $24.0M | -64.8% | $-63.5M | $-70.9M | $— | — |